Dry Eye

The analysis, which pulled data from the DRy Eye Assessment and Management (DREAM) study, found that users of corticosteroids had multiple worse and consistent DED signs.

Multiple symptomatic improvements, as well as tear film break-up time improvements and a reduction in ocular pain, were noted.

The transient receptor potential melastatin 8 (TRPM8) are cold-sensitive thermoreceptors that play central role in tear film homeostasis.

Education, together with strong recommendations, in-office retail, habit hacks, and follow-up visits, supports patient compliance.

Phase 3 of the randomized, double-masked, placebo-controlled study had a primary end point to evaluate the signs and symptoms of dry eye disease caused by Sjögren syndrome.

By targeting tear evaporation, F6H8 ushers in a new era of dry eye treatment.

Harrow’s Vevye is the first and only cyclosporine-based product approved for the treatment of both signs and symptoms of dry eye disease.

AR-15512 is a topical transient receptor potential melastatin 8 (TRPM8) agonist designed to treat the signs and symptoms of DED via increased tear production.

According to OKYO Pharma, the first-in-human, randomized, double-masked, placebo-controlled trial of OK-101 “established a clear and informed path for further development in Phase 3 registration trials.”

Dry eye disease incidence rates vary markedly depending on the eye care practice.

Vezocolmitide is the first drug candidate based on PolyCol, Stuart Therapeutics' patented synthesized polypeptide collagen mimetic peptide platform.

A look back at some of the biggest stories in ophthalmology in 2023.

Kelly K. Nichols, OD, MPH, PhD, FAAO, and A. Paul Chous, OD, FAAO, recap the diverse topics at EyeCon 2023, emphasizing the collaborative spirit between optometrists and ophthalmologists in addressing issues such as myopia management, diabetic eye conditions, cataract surgery, and patient referrals.

According to the company, an additional trial is required to show positive effects on the treatment of ocular symptoms in dry eye disease.

2 cases illustrate the importance of ocular surface optimization.

Using the NEI protocol for addressing corneal staining, researchers used 5 microliters of 2%, non preserved fluorescein and then evaluated corneal staining.

By taking a proactive approach to treatment, identify the “silent sufferers.”

According to Sun Pharmaceutical Industries, the study design mirrors real-world experience with dry eye disease, including allowing use of artificial tears and measurement of CFS in all 5 corneal zones.

The FDA recalled 26 eye drops due to risk of infection and possible vision loss.

These toxic offenders can be found in various pathways and can pollute the ocular surface.

Educating patients about the importance of consistent care is key.

TearCare provides significant improvements in dry eye signs and symptoms, superior to Restasis in tear film break-up time improvements.

Dr David Kading presents a case of MGD associated with extreme inflammatory reaction.

Retain patients and recapture dropouts with a tandem approach.

Collaboration between ophthalmologists, optometrists can boost early detection.

A rapid fire session details what's in the pipeline for ocular surface dryness therapies.

Aldeyra Therapeutics encounters a significant setback, with its stock value plummeting nearly 70%. The FDA indicates a potential Complete Response Letter (CRL) for reproxalap, a dry eye treatment, despite a scheduled Prescription Drug User Fee Act (PDUFA) date of November 23, 2023.

Tracy Doll, OD, FAAO, chats about the AAOpt session "Sunny With a Chance of Tears: What's in the Forecast for Ocular Surface Dryness Therapies?"